Literature DB >> 34401974

Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury.

Baolin Niu1, Xiaohong Lei2, Qingling Xu3, Yi Ju1, Dongke Xu1, Liya Mao1, Jing Li2, Yufan Zheng1, Ning Sun1, Xin Zhang4, Yimin Mao5, Xiaobo Li6.   

Abstract

Acetaminophen (APAP) overdose is a common cause of drug-induced liver injury (DILI). Ferroptosis has been recently implicated in APAP-induced liver injury (AILI). However, the functional role and underlying mechanisms of mitochondria in APAP-induced ferroptosis are unclear. In this study, the voltage-dependent anion channel (VDAC) oligomerization inhibitor VBIT-12 and ferroptosis inhibitors were injected via tail vein in APAP-injured mice. Targeted metabolomics and untargeted lipidomic analyses were utilized to explore underlying mechanisms of APAP-induced mitochondrial dysfunction and subsequent ferroptosis. As a result, APAP overdose led to characteristic changes generally observed in ferroptosis. The use of ferroptosis inhibitor ferrostatin-1 (or UAMC3203) and iron chelator deferoxamine further confirmed that ferroptosis was responsible for AILI. Mitochondrial dysfunction, which is associated with the tricarboxylic acid cycle and fatty acid β-oxidation suppression, may drive APAP-induced ferroptosis in hepatocytes. APAP overdose induced VDAC1 oligomerization in hepatocytes, and protecting mitochondria via VBIT-12 alleviated APAP-induced ferroptosis. Ceramide and cardiolipin levels were increased via UAMC3203 or VBIT-12 in APAP-induced ferroptosis in hepatocytes. Knockdown of Smpd1 and Taz expression responsible for ceramide and cardiolipin synthesis, respectively, aggravated APAP-induced mitochondrial dysfunction and ferroptosis in hepatocytes, whereas Taz overexpression protected against these processes. By immunohistochemical staining, we found that levels of 4-hydroxynonenal (4-HNE) protein adducts were increased in the liver biopsy samples of patients with DILI compared to that in those of patients with autoimmune liver disease, chronic viral hepatitis B, and non-alcoholic fatty liver disease (NAFLD). In summary, protecting mitochondria via inhibiting VDAC1 oligomerization attenuated hepatocyte ferroptosis by restoring ceramide and cardiolipin content in AILI.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  4-hydroxynonenal; Acetaminophen-induced liver injury; Ferroptosis; Mitochondria; VDAC1

Mesh:

Substances:

Year:  2021        PMID: 34401974     DOI: 10.1007/s10565-021-09624-x

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  54 in total

1.  Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy.

Authors:  Lars Devisscher; Samya Van Coillie; Sam Hofmans; Dries Van Rompaey; Kenneth Goossens; Eline Meul; Louis Maes; Hans De Winter; Pieter Van Der Veken; Peter Vandenabeele; Tom Vanden Berghe; Koen Augustyns
Journal:  J Med Chem       Date:  2018-11-06       Impact factor: 7.446

2.  Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.

Authors:  Danya Ben-Hail; Racheli Begas-Shvartz; Moran Shalev; Anna Shteinfer-Kuzmine; Arie Gruzman; Simona Reina; Vito De Pinto; Varda Shoshan-Barmatz
Journal:  J Biol Chem       Date:  2016-10-13       Impact factor: 5.157

3.  Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes.

Authors:  Yuichi Baba; Jason K Higa; Briana K Shimada; Kate M Horiuchi; Tomohiro Suhara; Motoi Kobayashi; Jonathan D Woo; Hiroko Aoyagi; Karra S Marh; Hiroaki Kitaoka; Takashi Matsui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-11-10       Impact factor: 4.733

Review 4.  Mitochondria as multifaceted regulators of cell death.

Authors:  Florian J Bock; Stephen W G Tait
Journal:  Nat Rev Mol Cell Biol       Date:  2019-10-21       Impact factor: 94.444

5.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

Authors:  Einar S Björnsson; Ottar M Bergmann; Helgi K Björnsson; Runar B Kvaran; Sigurdur Olafsson
Journal:  Gastroenterology       Date:  2013-02-16       Impact factor: 22.682

6.  Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.

Authors:  Rachel J Church; Gerd A Kullak-Ublick; Jiri Aubrecht; Herbert L Bonkovsky; Naga Chalasani; Robert J Fontana; Jens C Goepfert; Frances Hackman; Nicholas M P King; Simon Kirby; Patrick Kirby; John Marcinak; Sif Ormarsdottir; Shelli J Schomaker; Ina Schuppe-Koistinen; Francis Wolenski; Nadir Arber; Michael Merz; John-Michael Sauer; Raul J Andrade; Florian van Bömmel; Thierry Poynard; Paul B Watkins
Journal:  Hepatology       Date:  2018-06-27       Impact factor: 17.425

7.  Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure.

Authors:  C Chen; G E Hennig; H E Whiteley; J C Corton; J E Manautou
Journal:  Toxicol Sci       Date:  2000-10       Impact factor: 4.849

Review 8.  Drug-induced liver injury.

Authors:  Raul J Andrade; Naga Chalasani; Einar S Björnsson; Ayako Suzuki; Gerd A Kullak-Ublick; Paul B Watkins; Harshad Devarbhavi; Michael Merz; M Isabel Lucena; Neil Kaplowitz; Guruprasad P Aithal
Journal:  Nat Rev Dis Primers       Date:  2019-08-22       Impact factor: 52.329

9.  Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.

Authors:  Chi Chen; Kristopher W Krausz; Yatrik M Shah; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

10.  Lysosomal Cholesterol Accumulation Sensitizes To Acetaminophen Hepatotoxicity by Impairing Mitophagy.

Authors:  Anna Baulies; Vicent Ribas; Susana Núñez; Sandra Torres; Cristina Alarcón-Vila; Laura Martínez; Jo Suda; Maria D Ybanez; Neil Kaplowitz; Carmen García-Ruiz; Jose C Fernández-Checa
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

View more
  4 in total

1.  Hepatic TGFβr1 Deficiency Attenuates Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Failure Through Inhibiting GSK3β-Nrf2-Mediated Hepatocyte Apoptosis and Ferroptosis.

Authors:  Sha Huang; Yuhua Wang; Shuwen Xie; Yuqi Lai; Chan Mo; Ting Zeng; Shanshan Kuang; Guanghui Deng; Chuying Zhou; Yuyao Chen; Shaohui Huang; Lei Gao; Zhiping Lv
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-02-21

Review 2.  Emerging Potential Therapeutic Targets of Ferroptosis in Skeletal Diseases.

Authors:  Xin Liu; Tianhao Wang; Wei Wang; Xiaolong Liang; Yating Mu; Yaozeng Xu; Jiaxiang Bai; Dechun Geng
Journal:  Oxid Med Cell Longev       Date:  2022-07-30       Impact factor: 7.310

3.  Exosomes Derived from Baicalin-Pretreated Mesenchymal Stem Cells Alleviate Hepatocyte Ferroptosis after Acute Liver Injury via the Keap1-NRF2 Pathway.

Authors:  Shuxian Zhao; Mengxin Huang; Lili Yan; Hao Zhang; Chenchen Shi; Jing Liu; Shousong Zhao; Hongbo Liu; Baogui Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-21       Impact factor: 7.310

4.  Mitochondrial event as an ultimate step in ferroptosis.

Authors:  Soo-Jin Oh; Masataka Ikeda; Tomomi Ide; Kyu Yeon Hur; Myung-Shik Lee
Journal:  Cell Death Discov       Date:  2022-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.